Physician profile
Glenna S Jackson
NPI 1003887779
$2,811.87
in general payments reported to CMS, 2019-2025
29 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $296 · 2023: $225 · 2024: $398 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $396.76 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $366.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $365.00 | 2019-2024 | Airsupra |
| Abbvie INC. | $260.39 | 2019-2025 | |
| Lilly USA, LLC | $178.15 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $163.24 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $149.81 | 2019-2020 | |
| Amarin Pharma, INC. | $124.13 | 2019 | |
| Glaxosmithkline, LLC. | $120.11 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $98.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $82.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $40.02 | 2024 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $31.86 | 2023 | Gemtesa |
| Genentech USA, INC. | $24.53 | 2019 | |
| Exact Sciences Corporation | $18.68 | 2023 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $18.48 | 2023 | |
| Supernus Pharmaceuticals, INC. | $17.90 | 2019 | |
| Shire North American Group INC | $17.52 | 2019 | |
| Abbott Laboratories | $17.05 | 2023 | Freestyle Libre 2 |
| Allergan, INC. | $16.45 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.28 | 2024 | Gvoke Hypopen |
| Ironshore Pharmaceuticals INC. | $14.70 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.81 | 2019 | |
| Currax Pharmaceuticals LLC | $12.79 | 2023 | Contrave |
| Hikma Pharmaceuticals USA | $11.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenna Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.